Heghine Khachatryan: Strengthening Maternal Resilience Against Postpartum Hemorrhage
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, shared End Postpartum Hemorrhage’s post on LinkedIn, adding:
”Postpartum Hemorrhage (PPH) remains a leading cause of maternal mortality worldwide — and anaemia is a critical, yet often underestimated, contributor.
Strengthening maternal resilience requires a systems-based approach:
- Early identification and treatment of iron deficiency and anaemia during pregnancy
- Structured risk stratification for bleeding
- Access to safe and sufficient blood products
- Integration of haemostasis expertise into obstetric care
- Multidisciplinary emergency preparedness protocols
In many low- and middle-income settings, the intersection of anaemia, limited transfusion capacity, and delayed haemorrhage control creates a preventable cascade of morbidity and mortality.
Addressing PPH is not only about emergency management — it is about prevention, preparedness, and equitable access to diagnostics and treatment.
As hematologists and health policy advocates, we must actively contribute to strengthening national strategies that integrate maternal haemostasis, blood systems, and public health infrastructure.
Maternal survival is a measure of health system equity.”
Quoting End Postpartum Hemorrhage’s post:
”Strengthening Maternal Resilience: Postpartum Haemorrhage (PPH) remains the leading cause of maternal mortality in Kenya.
A critical factor often overlooked is pre-existing anaemia. Addressing this at the antenatal stage is a cost-effective, high-impact strategy for reducing deaths.”
Find more posts featuring Heghine Khachatryan on Hemostasis Today.
-
Mar 7, 2026, 16:24Kalpana Gupta Shekhawat: The Overlooked Regulator of Mast Cells – Understanding the Vagus Nerve
-
Mar 7, 2026, 16:20Purusotham Chippala: How DALYs Reveal the True Burden of Stroke
-
Mar 7, 2026, 16:13Ilenia Calcaterra: Patient-Level Real-World Outcomes of Emicizumab in Acquired Hemophilia A
-
Mar 7, 2026, 16:05Iyas Daghlas: DOACs Use, Genetic Reduction of Coagulation Factors and Risk of Cerebral Venous Thrombosis
-
Mar 7, 2026, 15:58Aurelio Maggio: The Mission and The Projects We Are Advancing for Rare Hematologic Diseases
-
Mar 7, 2026, 15:52Faizan Khan: The Importance of Cancer Site in Bleeding Risk Stratification for Cancer-Associated VTE
-
Mar 7, 2026, 15:50Heghine Khachatryan: How DOACs Can Cause False-Positive FVIII Inhibitor Results
-
Mar 7, 2026, 15:43Gevorg Tamamyan Joins The London Global Cancer Week Steering Group
-
Mar 7, 2026, 15:36Kenneth Monaghan: Empowering Stroke Survivors’ Self-Efficacy Through Neuroplasticity and Daily Activity